Hydroxocobalamin as a Cause of Oxalate Nephropathy
To the Editor: I read with interest the recently published article by Lumlertgul et al. regarding secondary oxalate nephropathy. 1 In this systematic review, the authors describe causes and outcomes of oxalate nephropathy by gathering data from case reports and case series. Unfortunately, the authors chose to restrict the literature search to exposure of more than 30 days before the diagnosis. In doing so, the authors missed the impact of short-term drug exposure. We recently described that hydroxocobalamin (Cyanokit, Merck Santé SAS) is associated with oxaluria and oxalate nephropathy. 2 Cyanokit is approved by the Food and Drug Administration for the treatment of cyanide poisoning. Hydroxocobalamin chelates cyanide to form cyanocobalamin, which is excreted by the kidneys. My colleagues and I described two cases of biopsy-proven oxalate nephropathy after exposure to Cyanokit. 2 Both patients presented with severe acute kidney injury (AKI). Furthermore, in a cohort of burn patients, the use of Cyanokit was significantly associated with the risk of AKI, even after adjustment for potential confounding factors. Oxaluria was also reported in healthy volunteers and animals receiving hydroxocobalamin. The Authors Reply: We thank Dr. Legrand for his comments regarding hydroxocobalamin as a cause of oxalate nephropathy. We opted to exclude patients with short-term exposure (<30 days) to hyperoxaluria-enabling conditions, as we assumed that these would be mostly accidental or intentional intoxications with short duration of follow-up (<1 month in most cases), and as a result might have a different prognosis compared to those in patients with longer exposure. In our systematic review, we provided a Supplementary Table S2 that summarizes the 23 excluded articles, totaling 50 patients who had shortterm exposure to hyperoxaluria-enabling conditions and a short follow-up period. All patients presented with acute kidney injury. Three patients had pre-existing chronic kidney disease. The median duration of followup was 1 month. The median duration of exposure was 16 hours. Of 50 patients, 54% required dialysis; 28 patients (56%) had complete recovery, 10 patients (20%) had partial recovery, and 12 patients (24%) remained dialysis dependent. The mortality rate was 24%. In our systematic review of patients with chronic exposure, 55% required dialysis. None had complete recovery, 42% had partial recovery, and 58% remained dialysis dependent. Of these patients, 33% died.
Although we failed to include hydroxocobalamin in Supplementary Table S2 due to incomplete information regarding onset of exposure, patient characteristics, and kidney and patient outcomes, we agree that the administration of hydroxocobalamin can cause oxalate nephropathy.
Hydroxocobalamin for injection (Cyanokit, Merck Santé s.a.s., Semoy, France) was approved by the U.S. Food and Drug Administration in 2006 for the treatment of cyanide poisoning. 1 Oxaluria has been observed in healthy volunteers and animals receiving hydroxocobalamin. 2 The administration of hydroxocobalamin at escalating doses (of 75 and 150 mg/kg, respectively) to cyanidepoisoned beagle dogs was not associated with a rise in the serum creatinine at day 2 and day 15. 3 However, in a series of smoke inhalation human victims treated with hydroxocobalamin that included cyanide-and nonÀcyanide-poisoned persons, a transient rise in the serum creatinine was observed during the 3-day study period. 4 Legrand et al. are the first to describe two critically ill burn patients with smoke inhalation injury who developed acute kidney injury requiring renal replacement therapy after receiving hydroxocobalamin, with evidence of oxalate crystal deposition in the renal tubules on kidney biopsy. Furthermore, in a cohort of burn patients, the use of hydroxocobalamin was significantly associated with an increase in urine oxalate excretion and an increased risk of acute kidney injury after adjustment for potential confounders.
5 Hendrix et al. also reported a kidney transplant donor who experienced a transient rise in serum creatinine after the administration of hydroxocobalamin and who, on kidney biopsy, had evidence of oxalate nephropathy, which resolved 6 weeks after transplantation. 6 However, another donor in this report who had also received hydroxocobalamin before death did not have oxalate crystal deposition on biopsy.
Although the mechanism of hydroxocobalaminassociated oxalate nephropathy is unknown, we can only speculate as to whether the oxalate deposition is related to the hydroxocobalamin per se or to some unknown toxicant(s) present in the smoke inhalation process. In addition, potential interactions between the dose of hydroxocobalamin, its volume of distribution, and renal clearance, as well as patient-related factors and concurrent therapies, might have an impact on oxalate crystallization in urine. In conclusion, although hydroxocobalamin might be associated with oxalate nephropathy, more studies are needed to address the kidney safety of this drug.
